PHRX - Pharmagen, Inc. due diligence PHRX Company

New Post Public Reply Private Reply Replies (1) Message Board
PYCKtradr
PHRX - Pharmagen, Inc. due diligence



PHRX Company Description
Pharmagen, Inc. ("Pharmagen"), and wholly owned subsidiaries and operating divisions Pharmagen Laboratories, Inc., Pharmagen Distribution, LLC and Pharmagen Nutraceuticals, Inc. offers innovative solutions to the nations sterile pharmaceutical crisis. With a multi-solution approach, Pharmagen is helping to meet the demand of the health provider market through independent wholesale, compounding, and IT solutions. Nationally focused, Pharmagen is a distributor of specialty drugs, compounding and admix pharmacy and producer of over-the-counter ("OTC") branded multivitamins. Pharmagen currently functions as a just-in-time source of supply for hospitals for those products that are hard-to-find due to drug manufacturers' production shortages.



PHRX Products and Services
Divisions

Pharmagen Laboratories
Pharmagen Laboratories’ specialties include: urology, pain management, hormone replacement, ophthalmology, respiratory diseases, mental and psychological disorders, oncology, gynecology, muscular and skeletal locomotion (MS), trauma and burn units, neo-natal compounding, hypoallergenic compounding, and veterinary compounding. Pharmagen assists with projects designed to prevent, diagnose, and treat immune/autoimmune-related illnesses and emerging/re-emerging diseases.

Starting with USP and NF quality chemicals and nutraceuticals, the registered pharmacists at Pharmagen can compound a full range of dosage forms. Unlike most pharmacies, Pharmagen has its own Certified ISO Class 5 sterile environment, permitting onsite compounding of intravitreal injections, diagnostic agents, multi-dose and unit-dose injections, sterile preservative-free ophthalmic ointments, and other specialized medications.

Adhering to all USP <797> and USP <795> regulations covering both sterile and non-sterile drug manipulations, Pharmagen’s in house sterility, potency, and stability quality control systems are also validated by third party analytical testing laboratories, Eagle Analytical of Houston, Texas.

Pharmagen is dedicated to finishing each compounded medication in a timely manner. With a state-of-the-art compounding facility, and pharmacists dedicated to excellence, Pharmagen is a sole source pharmaceutical provider. Every compounded medication shipped is analyzed to ensure the end product meets the patient’s individual requirements.

Pharmagen Distribution
At Pharmagen Distribution, we are deeply committed to our clients and their success, and we take tremendous pride in our work. Our passion for excellence drives us to constantly strive toward exceeding the needs of our clients. Pharmagen is a national specialty pharmaceutical distribution company dedicated to servicing multi-specialty clinics, surgery centers, and physicians. Our product offerings include full-line brand pharmaceuticals, injectables, vaccines, and a highly competitive generics portfolio. We work directly with manufacturers as well as multiple suppliers, giving us the best network to source the products you need.

Through a dynamic, independent wholesale model, our team can supply almost any drug product in both small and large quantities including hard-to-find items. We can source branded, generic, and OTC products in all therapeutic classes and dosage forms. Lot and expiration date requirements are always followed. We have a proven track record shipping domestically and internationally to depots, clinical sites, sponsor companies, and clinical packagers around the globe.

Pharmagen offers a full line of products including plasma derivatives, oncology, women’s health, vaccines, surgical, and orthopedic.

Pharmagen Neutraceuticals
At Pharmagen Nutraceuticals, we manufacture and distribute over-the-counter (OTC) branded health supplements. Our innovative approach to OTC is to create suites of products designed to work in conjunction with prescription medications to alleviate side effects or prevent drug interactions. With an aging population, more Americans than ever rely on prescription medications. We are currently analyzing several OTC products that would allow us to become a powerful player in the multi-billion-dollar health supplement market.

Pharmagen’s first OTC product, Clotamin™, is available nationally at various retail outlets. Over 30 million prescriptions are written each year in the United States for Warfarin, an anticoagulant also known under many brand names including Coumadin™. Some pharmacists have been reluctant to recommend vitamin supplements to patients on blood thinners because of possible interactions with Warfarin therapy. Clotamin™ is the first product on the market that is designed to work in conjunction with anticoagulation therapy.

Licenses/ Accreditations
Pharmagen is licensed in Arkansas, Alaska, California, Colorado, Connecticut, Delaware, Washington, D.C., Georgia, Hawaii, Idaho, Illinois, Iowa, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina,, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, South Dakota, Texas, Utah, Vermont, Washington, West Virginia, and Wisconsin.

Accreditations & Memberships
North Carolina Biosciences Organization
PCAB Certification Pending
USP <797> Compliant Facility
USP <795> Compliant Facility
FDA Inspected
ISO Class 5 cleanrooms with Laminar Flow Hoods
Good Laboratory Practice Facility
D.E.A. Registration
PCCA Member in Good Standing



PHRX Key Company Management
Mackie Barch, CEO
Before launching Pharmagen, Mr. Barch cofounded Global Nutritional Research, manufacturers of over-the-counter (OTC) products for specific disease states based on Rx/OTC interaction. Since 2007, he has been involved in numerous financial and operational aspects of pharmaceutical companies operating in the secondary wholesale market. Prior to that, Mr. Barch worked in the financial services industry, where he was employed at Friedman, Billings, & Ramsey (FBR) from 2001 to 2006. He has participated in numerous equity offerings including 144a, IPO, and Secondary Offerings. He has extensive business experience and familiarity with a wide range of businesses and strategies in industries including Financial, Energy, Technology, Healthcare, and Consumer. He graduated from University of Colorado-Boulder with a BA in Economics. Barch is currently an elected official in the State of Maryland, serving as a City Council Member in Kensington, MD. Barch was President of the National Blood Clot Alliance Chapter in Washington, D.C., hosting charity events to raise awareness about the prevalence of thrombophilia and blood clot prevention.

Eric Clarke CFO
Mr. Clarke brings more than 17 years of extensive healthcare and financial expertise. Prior to joining Pharmagen, Clarke served as part of the leadership team at MedStar Health, a $4 billion diversified health system in the Washington, D.C. region, which includes leading medical facilities such as Washington Hospital Center and Georgetown University Hospital. As the leader in charge of the Internal Audit function, Clarke oversaw all financial and operational audits, was instrumental in building an effective internal audit function, and reported to the Audit and Compliance Committee. Prior to MedStar, Clarke served as Managing Director in charge of the Washington D.C., Risk Management Practice for a national professional services firm, providing expert advice and services in forensic accounting, SEC reporting, and Sarbanes-Oxley Compliance. Clarke has authored numerous presentations and articles in the accounting and compliance arena, and has been featured in several publications such as Compliance Week and Practical Accountant. As a member of the Virginia Society of Certified Public Accountants, Clarke holds a Master's degree in Accounting from George Washington University and a Bachelor's Degree from Wheaton College.

PHRX Contact Info
Pharmagen, Inc.
9337 Fraser Avenue
Silver Spring, MD 20910

Website: http://www.pharmageninc.com
Phone: 204-898-8160
Email: info@pharmagenrx.com

PHRX SEC Filings
http://www.otcmarkets.com/stock/PHRX/filings

PHRX Headlines
http://finance.yahoo.com/q/h?s=PHRX+Headlines

Investigate more about PHRX @ http://www.otcmarkets.com/stock/PHRX/quote for more due diligence.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hi3D Unlocks AI 3D Model for Open-Source Innovation

Updated Category News Views 4

A New Era in 3D Model Accessibility Unless you’ve been hiding under a rock, it’s hard to miss how digital terraforming has shifted gears. With Hi3D V1.0 opening its doors, the playing field's getting a major reshuffle. Or, as they say, the table is being set, and everyone's getting a seat. By letting loose production-validated AI tools, Hi3D is throwing down the...

Continue Reading
Full-Life's FL-020 Shows Promise for Prostate Cancer

Updated Category News Views 3

Breaking New Ground in Prostate Cancer Treatment You know, it’s not every day you stumble across news in the medical field that perks up the ears of investors, but let me tell ya, Full-Life Technologies' latest data drop has certainly caught my attention. If there’s even a smidge of truth in these findings, we might have a game-changer on our hands in the realm of...

Continue Reading
HawkEye 360 Expands with Advanced Satellite Launch

Updated Category News Views 4

Another Triumph for Signals Intelligence Launches come and go, but HawkEye 360's recent deployment of Cluster 16 isn't just another tick on their list. This satellite trio is kitted out with tech that propels the firm deeper into the realm of signals intelligence, where every second counts. The Art of Keeping Up with Demand Now, it's no simple feat to manage rocket...

Continue Reading
AHN Launches Cancer Screenings at Work; Dollar Bank First

Updated Category News Views 35

Pioneering Workplace Cancer Screening Initiative In a move that could redefine preventive healthcare, Allegheny Health Network (AHN) Cancer Center is taking cancer screenings right to the workplace. This initiative isn't just a new gimmick—it's a smart pivot in delivering healthcare where it's most convenient for employees. Here's looking at you, Dollar Bank, for being...

Continue Reading
Lowcountry Kids to Get Free Helmets at Safety Events

Updated Category News Views 1

Helmets for Kids Initiative Gets Rolling Now, here's a story that's more about community care than cash flow, but hey, sometimes even a grizzled trader like me can nod in appreciation. Christmas Injury Lawyers are putting their money where their mouth is, with the Helmets for Kids initiative staged at two key events in the Lowcountry area. Yep, that's right—the legal...

Continue Reading
VoxNexus Debuts On-Device AI: A Game-Changer for Languages

Updated Category News Views 0

VoxNexus Changes the Game with VoxEdge Here's the rub with tech: it often feels like it's only for the folks who already have a leg up. VoxNexus just flipped the script with its new product, VoxEdge, an on-device voice stack that's making waves by breaking language barriers in the ever-evolving AI world. This move might just shift the landscape of voice artificial...

Continue Reading
Corgi Invest Shakes Up Bond ETFs with Low Fees

Updated Category News Views 4

A Different Breed of Bond ETFs Well, folks, when you thought the ETF scene couldn't get any more crowded, Corgi Invest pops in with a pack of 14 new bond ETFs, barking up the low-expense tree like there's no tomorrow. They've dropped these puppies into the market with fees starting as low as 0.02%, aiming to take a bite out of their pricier rivals. The Alpha of Low-Cost...

Continue Reading
Harbour BioMed's Batoclimab Injected Into Myasthenia Market

Updated Category News Views 6

China's Green Light for Batoclimab When a new drug approval hits, particularly in a crucial market like China, it's a big deal. Harbour BioMed's recent go-ahead from the National Medical Products Administration (NMPA) for their Batoclimab injection is no exception. This marks the first full clinical cycle completion of an anti-FcRn treatment for generalized myasthenia...

Continue Reading
Ellington's Q3 Earnings Call: What Investors Need to Know

Updated Category News Views 6

An Anticipated Unveiling Ellington Financial Inc. (NYSE:EFC) is gearing up to spill the beans on its third-quarter financials for 2026. It's all going down after the markets close on November 4th. I can tell you, folks, anyone keeping an eye on EFC will be itching to know what's inside those numbers. With a company this deep into financial assets, reading between the...

Continue Reading
Data Center Cooling Market to Hit $1B by 2033

Updated Category News Views 3

The Heat's On: Immersion Cooling Fluid Market Booms Kicking off with numbers straight out of the gate, data center immersion cooling fluids are gearing up for a wild ride. From just $0.23 billion back in 2026, this market is on a blitz to hit a whopping $1.06 billion by 2033. We're talking a hefty 24.8% compound annual growth rate. That's no small shakes. Race for Energy...

Continue Reading

Top 5 Most Recently Viewed Articles

United Therapeutics: Understanding Market Sentiment and Trends

Updated Category News Views 392

Market Sentiment Towards United Therapeutics United Therapeutics (NYSE: UTHR) has seen a notable increase in its short percent of float, rising to 7.82% since the last report. Currently, there are approximately 2.24 million shares sold short, equating to 6.62% of all regular shares available for trading. This trend indicates a growing cautious stance among some investors,...

Continue Reading
Canoe EIT Income Fund Reveals Monthly and Quarterly Distributions

Updated Category News Views 126

Canoe EIT Income Fund’s Distribution Announcements In the ever-evolving landscape of investment funds, the Canoe EIT Income Fund has made significant waves with its recent distribution announcements. The Fund, expertly managed and one of Canada’s premier closed-end investment opportunities, is prepared to offer a monthly distribution amounting to $0.10 per unit. This...

Continue Reading
ADMA Investors Evaluate Class Action Amidst Allegations

Updated Category News Views 9

Securities Fraud Allegations Cast Shadow Over ADMA Well, here we are again, wading through another mess in the biopharma world. This time, it's ADMA Biologics (NASDAQ: ADMA) in the spotlight, and not for their groundbreaking treatments. Nope, this one's about securities fraud allegations and, boy, do investors need to brace themselves. You got Berger Montague PC, those...

Continue Reading
Market Shifts: Navigating the Latest Trends in Trading

Updated Category News Views 266

Indices: An Overview of Uncertain Factors US equity index futures are stabilizing following a session marked by a remarkable rebound from previous lows, leading to higher closes for various indices. The S&P 500 rose by 0.4%, while the Nasdaq 100 surged up 0.7%, and the Dow 30 saw an increase of 0.5%. Notably, the small-cap Russell 2000 experienced the most significant...

Continue Reading
Primech A&P: A Trailblazer in Facility Management Excellence

Updated Category News Views 150

Primech A&P Achieves Prestigious Recognition in Facility Management With great pride, Primech Holdings Limited celebrates a significant milestone achieved by its subsidiary, Primech A&P Pte. Ltd. This notable recognition, the ASEAN Public Toilet Award, was presented in honor of Primech A&P's incredible management and upkeep of public facilities at Newton Food Centre....

Continue Reading